RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinomaLADERO, J. M; AGUNDEZ, J. A. G; RODRIGUEZ-LESCURE, A et al.Gut. 1996, Vol 39, Num 2, pp 330-333, issn 0017-5749Article

Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 studyPICO, C; MARTIN, M; DE LA HABA, J et al.Annals of oncology. 2004, Vol 15, Num 1, pp 79-87, issn 0923-7534, 9 p.Article

Predicting response and survival in chemotherapy-treated triple-negative breast cancerPRAT, A; LLUCH, A; SEGUI-PALMER, M. A et al.British journal of cancer. 2014, Vol 111, Num 8, pp 1532-1541, issn 0007-0920, 10 p.Article

Clinical activity of chronic oral etoposide in previously treated metastatic breast cancerMARTIN, M; LLUCH, A; DIAZ-RUBIO, E et al.Journal of clinical oncology. 1994, Vol 12, Num 5, pp 986-991, issn 0732-183XArticle

Prednimustine-induced myoclonus : a report of three casesMARTIN, M; DIAZ-RUBIO, E; CASADO, A et al.Acta oncologica (Stockholm). 1994, Vol 33, Num 1, pp 81-82, issn 0284-186XArticle

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)AAPRO, M; MOLASSIOTIS, A; ROILA, F et al.Annals of oncology. 2012, Vol 23, Num 8, pp 1986-1992, issn 0923-7534, 7 p.Article

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) : impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimenMARTIN, M; LLUCH, A; ROSET, M et al.Annals of oncology. 2006, Vol 17, Num 8, pp 1205-1212, issn 0923-7534, 8 p.Article

Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicinNIETO, Y; MARTIN, M; ALONSO, J. L et al.Breast cancer research and treatment. 1998, Vol 50, Num 2, pp 167-174, issn 0167-6806Article

Acute and anticipatory emesis in breast cancer patientsFERNANDEZ-MARCOS, A; MARTIN, M; SANCHEZ, J. J et al.Supportive care in cancer. 1996, Vol 4, Num 5, pp 370-377, issn 0941-4355Article

Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizersAGUNDEZ, J. A. G; OLIVERA, M; LADERO, J. M et al.Pharmacogenetics (London). 1996, Vol 6, Num 6, pp 501-512, issn 0960-314XArticle

CYP2D6 genes and risk of liver cancerAGUNDEZ, J. A. G; LEDESMA, M. C; BENITEZ, J et al.Lancet (British edition). 1995, Vol 345, Num 8953, pp 830-831, issn 0140-6736Article